Literature DB >> 22565213

Comparison of commercial molecular assays for toxigenic Clostridium difficile detection in stools: BD GeneOhm Cdiff, XPert C. difficile and illumigene C. difficile.

Céline Viala1, Alban Le Monnier, Naouale Maataoui, Clotilde Rousseau, Anne Collignon, Isabelle Poilane.   

Abstract

Three commercial molecular assays were evaluated for toxigenic Clostridium difficile detection in stools. As compared to toxigenic culture, BD GeneOhm Cdiff (BD Diagnostics), XPert C. difficile (Cepheid) and illumigene C. difficile (Meridian Bioscience) demonstrated respectively a sensitivity of 95.5%, 97.8% and 86.7% and a specificity of 97.9%, 97.9% and 100%.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22565213     DOI： 10.1016/j.mimet.2012.04.017

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN： 0167-7012            Impact factor:   2.363


  23 in total

1.  Reply to "Comparison of detection methods for Clostridium difficile".

Authors:  P Pancholi; C Kelly; M Raczkowski; J M Balada-Llasat
Journal:  J Clin Microbiol       Date:  2013-05       Impact factor: 5.948

Review 2.  Emerging technologies for the clinical microbiology laboratory.

Authors:  Blake W Buchan; Nathan A Ledeboer
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

3.  Comparison of Illumigene, Simplexa, and AmpliVue Clostridium difficile molecular assays for diagnosis of C. difficile infection.

Authors:  E Deak; S A Miller; R M Humphries
Journal:  J Clin Microbiol       Date:  2013-12-18       Impact factor: 5.948

4.  Evaluation of Clostridium difficile fecal load and limit of detection during a prospective comparison of two molecular tests, the illumigene C. difficile and Xpert C. difficile/Epi tests.

Authors:  Clare E Gyorke; Susan Wang; Jhansi L Leslie; Stuart H Cohen; Jay V Solnick; Christopher R Polage
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

5.  Multicenter evaluation of the Quidel Lyra Direct C. difficile nucleic acid amplification assay.

Authors:  Eric T Beck; Blake W Buchan; Katherine M Riebe; Brenda R Alkins; Preeti Pancholi; Paul A Granato; Nathan A Ledeboer
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

Review 6.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

7.  Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens.

Authors:  Blake W Buchan; Tami-Lea A Mackey; Judy A Daly; Garrison Alger; Gerald A Denys; Lance R Peterson; Sue C Kehl; Nathan A Ledeboer
Journal:  J Clin Microbiol       Date:  2012-09-26       Impact factor: 5.948

8.  Multicenter evaluation of the Verigene Clostridium difficile nucleic acid assay.

Authors:  Karen C Carroll; Blake W Buchan; Sokha Tan; Paul D Stamper; Katherine M Riebe; Preeti Pancholi; Cheryl Kelly; Arundhati Rao; Robert Fader; Robert Cavagnolo; Wendy Watson; Richard V Goering; Ernest A Trevino; Alice S Weissfeld; Nathan A Ledeboer
Journal:  J Clin Microbiol       Date:  2013-10-02       Impact factor: 5.948

9.  C. difficile ribotype 027 or 176?

Authors:  Marcela Krutova; Jana Matejkova; Otakar Nyc
Journal:  Folia Microbiol (Praha)       Date:  2014-06-27       Impact factor: 2.099

10.  Evaluation of the fully automated BD MAX Cdiff and Xpert C. difficile assays for direct detection of Clostridium difficile in stool specimens.

Authors:  Alexander H Dalpke; Marjeta Hofko; Markus Zorn; Stefan Zimmermann
Journal:  J Clin Microbiol       Date:  2013-03-20       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.